Oncology Molecular Diagnostic Trends and Forecast
The future of the global oncology molecular diagnostic market looks promising with opportunities in the hospital and diagnostic center, reference laboratory, pharmaceutical and biotechnology, and academic & research institute markets. The global oncology molecular diagnostic market is expected to reach an estimated $7.3 billion by 2030 with a CAGR of 13.2% from 2024 to 2030. The major drivers for this market are augmenting incidence of different cancer related cases, increasing demand for rapid and accurate diagnosis, and growing number of blood donation campaigns.A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Oncology Molecular Diagnostic by Segment
The study includes a forecast for the global oncology molecular diagnostic by product type, type, technology, end use, and region.Oncology Molecular Diagnostic Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:
- Instruments
- Reagents
- Others
Oncology Molecular Diagnostic Market by Type [Shipment Analysis by Value from 2018 to 2030]:
- Blood Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Liver Cancer
- Lung Cancer
- Skin Cancer
- Cervical Cancer
- Others
Oncology Molecular Diagnostic Market by Technology [Shipment Analysis by Value from 2018 to 2030]:
- Polymerase Chain Reaction (PCR)
- In-situ Hybridization (ISH)
- Isothermic Nucleic Acid Amplification Technology (INNAT)
- Chips & Microarrays
- Sequencing
- Mass Spectroscopy
- Transcription Mediated Amplification (TMA)
- Others
Oncology Molecular Diagnostic Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
- Hospitals and Diagnostic Centers
- Reference Laboratories
- Pharmaceutical and Biotechnology
- Academic & Research Institutes
- Others
Oncology Molecular Diagnostic Market by Region [Shipment Analysis by Value from 2018 to 2030]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of Oncology Molecular Diagnostic Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies oncology molecular diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the oncology molecular diagnostic companies profiled in this report include-- Abbott
- Becton
- Dickinson
- F. Hoffmann-La Roche
- Cepheid
- Bayer
- Agilent Technologies
- Danaher
- Hologic
- Sysmex
Oncology Molecular Diagnostic Market Insights
The publisher forecasts that breast is expected to witness highest growth over the forecast period due to increasing awareness of breast cancer and women's health and rising demand for minimally invasive and accurate diagnostic tests.Within this market, hospital and diagnostic center is expected to witness highest growth over the forecast period due to the extensive use of molecular diagnostic tests in this field by medical proffesionals.
North America is expected to witness highest growth over the forecast period due to rising prevalence of cancer among population, existence of favorable reimbursement for health, and presence of key players in the region.
Features of the Global Oncology Molecular Diagnostic Market
- Market Size Estimates: Oncology molecular diagnostic market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
- Segmentation Analysis: Oncology molecular diagnostic market size by various segments, such as by product type, type, technology, end use, and region in terms of ($B).
- Regional Analysis: Oncology molecular diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different product types, types, technologies, end uses, and regions for the oncology molecular diagnostic market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the oncology molecular diagnostic market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q.1 What is the oncology molecular diagnostic market size?Answer: The global oncology molecular diagnostic market is expected to reach an estimated $7.3 billion by 2030.
Q.2 What is the growth forecast for oncology molecular diagnostic market?
Answer: The global oncology molecular diagnostic market is expected to grow with a CAGR of 13.2% from 2024 to 2030.
Q.3 What are the major drivers influencing the growth of the oncology molecular diagnostic market?
Answer: The major drivers for this market are augmenting incidence of different cancer related cases, increasing demand for rapid and accurate diagnosis, and growing number of blood donation campaigns.
Q4. What are the major segments for oncology molecular diagnostic market?
Answer: The future of the oncology molecular diagnostic market looks promising with opportunities in the hospital and diagnostic center, reference laboratory, pharmaceutical and biotechnology, and academic & research institute markets.
Q5. Who are the key oncology molecular diagnostic market companies?
Answer: Some of the key oncology molecular diagnostic companies are as follows:
- Abbott
- Becton
- Dickinson
- F. Hoffmann-La Roche
- Cepheid
- Bayer
- Agilent Technologies
- Danaher
- Hologic
- Sysmex
Answer: The publisher forecasts that breast is expected to witness highest growth over the forecast period due to increasing awareness of breast cancer and women's health and rising demand for minimally invasive and accurate diagnostic tests.
Q7. In oncology molecular diagnostic market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness highest growth over the forecast period due to rising prevalence of cancer among population, existence of favorable reimbursement for health, and presence of key players in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, the publisher provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the oncology molecular diagnostic market by product type (instruments, reagents, and others), type (blood cancer, breast cancer, prostate cancer, colorectal cancer, liver cancer, lung cancer, skin cancer, cervical cancer, and others), technology (polymerase chain reaction (PCR), in-situ hybridization (ISH), isothermic nucleic acid amplification technology (INNAT), chips & microarrays, sequencing, mass spectroscopy, transcription mediated amplification (TMA), and others), end use (hospitals and diagnostic centers, reference laboratories, pharmaceutical and biotechnology, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Global Oncology Molecular Diagnostic Market : Market Dynamics
3. Market Trends and Forecast Analysis from 2018 to 2030
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
5. Competitor Analysis
6. Growth Opportunities and Strategic Analysis
7. Company Profiles of Leading Players
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott
- Becton
- Dickinson
- F. Hoffmann-La Roche
- Cepheid
- Bayer
- Agilent Technologies
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.
LOADING...
